AVENUE THERAPEUTICS, INC. (ATXI)
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Avenue Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 3.29M shares outstanding
USAvenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
Leadership
Alexandra MacLean, M.D.
Director
Curtis Oltmans
Director
Faith Charles
Director
Jay Kranzler, M.D., PhD
Chairman of the Board of Directors
Employees
1
Country
US
Sector
Healthcare
Website
avenuetx.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Fortress Biotech, Inc. | 10% Owner | Grant/Award | 111.2K | -- | Jan 2, 2026 |
| Fortress Biotech, Inc. | 10% Owner | Grant/Award | 33.7K | -- | Mar 31, 2025 |
 Herskowitz Neil | Director | Sale | 23 | $46 | Dec 2, 2024 |
 KRANZLER JAY D | Director | Sale | 61 | $136.64 | Nov 5, 2024 |
| KRANZLER JAY D | Director | Purchase | 497 | $1.2K | Sep 30, 2024 |
| KRANZLER JAY D | Director | Purchase | 3 | $7.2 | Sep 27, 2024 |
| Name | Shares | % | Source |
|---|---|---|---|
Fortress Biotech, Inc. · may incl. warrants· filed Jan 2026 | 440.0K | 13.4% | 13D |
 MacLean Alexandra Chief Executive Officer, Director | 170.0K | 5.2% | FORM 4 |
Ikarian Capital, LLC · may incl. warrants· filed Feb 2026 | 130.8K | 4.0% | 13G |
Armistice Capital, LLC · may incl. warrants· filed Feb 2025 | 100.4K | 3.0% | 13G |
 Jin David Interim PFO and COO | 65.0K | 2.0% | FORM 4 |
Robert Davidow · may incl. warrants· stale · filed May 2024 | 17.2K | 0.5% | 13G |
Sabby Volatility Warrant Master Fund, Ltd. · filed Jan 2024 | 8.8K | 0.3% | 13G |
 KRANZLER JAY D Director | 559 | 0.0% | FORM 4 |
 Herskowitz Neil Director | 97 | 0.0% | FORM 4 |
Insiders
- Fortress Biotech, Inc.10% Owner
- Herskowitz NeilDirector
- KRANZLER JAY DDirector
- MacLean AlexandraChief Executive Officer
- Charles Faith L.Director
- Jin DavidInterim PFO and COO
- ROSENWALD LINDSAY A MDDirector
- Oltmans Curtis GaleDirector
based on 3.29M shares outstanding
US30d Avg
5.33K
60d Avg
9.13K
90d Avg
9.38K